Meeting NewsVideo

VIDEO: Synthetic control group successful in multiple myeloma study

ORLANDO — At the ASH Annual Meeting and Exposition, Bryant Fields, senior director of integrated evidence at Acorn AI, a Medidata Solutions company, discusses the use of synthetic control arms in clinical trials.

Fields and his team were able to effectively replicate a control group using a synthetic approach in a multiple myeloma study.

“This represents another step in validating this approach to bring a treatment to the industry faster, but more importantly with a higher degree of scientific certainty to multiple myeloma patients and other indications we’re providing access to, in some cases, very lifesaving treatments faster,” Fields told HemOnc Today. – by Alaina Tedesco

Disclosure: Fields reports being a senior director at Medidata Solutions.

ORLANDO — At the ASH Annual Meeting and Exposition, Bryant Fields, senior director of integrated evidence at Acorn AI, a Medidata Solutions company, discusses the use of synthetic control arms in clinical trials.

Fields and his team were able to effectively replicate a control group using a synthetic approach in a multiple myeloma study.

“This represents another step in validating this approach to bring a treatment to the industry faster, but more importantly with a higher degree of scientific certainty to multiple myeloma patients and other indications we’re providing access to, in some cases, very lifesaving treatments faster,” Fields told HemOnc Today. – by Alaina Tedesco

Disclosure: Fields reports being a senior director at Medidata Solutions.

    See more from Discoveries from ASH: Multiple Myeloma